IMMUNITYBIO
LIVE

Serial Number

97594882

Owner

NANTCELL, INC.

Attorney

MICHAEL J MCCUE

First Use Date

Jan 18, 2022

Filing Date

Sep 16, 2022

Add to watchlist:

No watchlists yet
View on USPTO

IMMUNITYBIO Trademark

Serial Number: 97594882

IMMUNITYBIO is a trademark filed by NANTCELL, INC. on September 16, 2022. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

NANTCELL, INC. (11 trademarks)

CULVER CITY, CA 90232

Entity Type: 03

Trademark Details

Filing Date

September 16, 2022

Registration Date

Not Registered

First Use Anywhere

January 18, 2022

First Use in Commerce

July 19, 2022

Goods & Services

Pharmaceutical preparations and substances for the treatment of human viral diseases, animal viral diseases, autoimmune diseases, infectious diseases and cancer for scientific, clinical, medicinal, therapeutic, and diagnostic purposes; pharmaceutical preparations and substances for the prevention, diagnosis, and treatment of human viral diseases, animal viral diseases, autoimmune diseases, infectious diseases and cancer; pharmaceutical and biological preparations for use in targeted immunotherapy for the treatment of human viral diseases, animal viral diseases, autoimmune diseases, infectious diseases and cancer; biological preparations for medical purposes, namely, vaccines for human use and animal use; low-dose chemotherapies, low dose radiation therapies, and personalized neoepitope-targeted therapies, all of the foregoing in the nature of pharmaceutical preparations for medical use for the treatment of human viral diseases, animal viral diseases, autoimmune diseases, infectious diseases, and cancer; anti-cancer preparations; vaccines; biologics, namely, cell-derived preparations, cell therapies, monoclonal antibodies, cytokines, immune modulators, low-dose chemotherapy, low-dose radiation therapy, antibodies, fusion proteins, peptide and cytokine biologics, vaccines, personalized neoepitope-based therapies, cell therapies, and natural killer cell derived preparations, all of the foregoing in the nature of pharmaceutical preparations for clinical, medicinal, therapeutic, and veterinary purposes for the prevention, diagnosis, and treatment of human viral diseases, animal viral diseases, autoimmune diseases, infectious diseases and cancer; kits for clinical, medicinal, therapeutic, and veterinary purposes comprised of clinical medical reagents, cell cultures media for laboratory use, and related printer user instructions sheets

Filing History

TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 8, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 8, 2025 CRFA
ASSIGNED TO LIE
Oct 8, 2025 ALIE
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Oct 1, 2025 ERFR
EX PARTE APPEAL-INSTITUTED
Oct 1, 2025 EXPI
JURISDICTION RESTORED TO EXAMINING ATTORNEY
Oct 1, 2025 JURT
EXPARTE APPEAL RECEIVED AT TTAB
Oct 1, 2025 EXAF
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Jun 26, 2025 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Jun 26, 2025 XELR
NOTIFICATION OF FINAL REFUSAL EMAILED
Apr 1, 2025 GNFN
FINAL REFUSAL E-MAILED
Apr 1, 2025 GNFR
FINAL REFUSAL WRITTEN
Apr 1, 2025 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 5, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 5, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 5, 2024 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
May 6, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
May 6, 2024 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 5, 2024 GNRN
NON-FINAL ACTION E-MAILED
Feb 5, 2024 GNRT
NON-FINAL ACTION WRITTEN
Feb 5, 2024 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 21, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 20, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 20, 2023 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Sep 27, 2023 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Sep 27, 2023 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 27, 2023 GNRN
NON-FINAL ACTION E-MAILED
Jun 27, 2023 GNRT
NON-FINAL ACTION WRITTEN
Jun 27, 2023 CNRT
ASSIGNED TO EXAMINER
Jun 27, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 3, 2022 NWOS
NEW APPLICATION ENTERED
Sep 20, 2022 NWAP